

Atty's Docket 101195-54

**CERTIFICATION OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner For Patents, Washington, D.C. 20231, on December 30, 2003.

  
Theodore Gottlieb**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

SERIAL NO.	09/869,508
APPLICANT	WOLFF et al.,
FILED	June 5, 2002
EXAMINER	Dave Trong N'Guyen
ART UNIT	1632
FOR	GENE TRANSFER VECTOR FOR THE DIAGNOSIS AND THERAPY OF MALIGN TUMORS

Commissioner of Patents  
PO BOX 1450  
Alexandria, VA 22313-1450

30 December 2003

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

This communication is in response to the office action of 30 June 2003

In addition to the submissions filed herewith, entry of any amendments and consideration of any remarks is respectfully solicited.

The computer readable diskette will follow shortly.

Atty's Docket 101195-54

**IN THE SPECIFICATION**

☒ In the above-referenced application, please add the sequence listing filed herewith to the specification.

☐ In the above-referenced application, please substitute the sequence listing filed herewith for the current sequence listing of record in the specification.

**CONDITIONAL PETITION FOR EXTENSION OF TIME**

If any extension of time for this response is required, Applicants request that this be considered a petition therefore. Please charge the required fee to Deposit Account No. 14-1263.

**ADDITIONAL FEES**

Please charge any further insufficiency of fees, or credit any excess to Deposit Account No. 14-1263.

**ITEMS BEING SUBMITTED**

The checked boxes indicate the items enclosed herewith:

- ☒ A paper copy of the sequence listing for the nucleotide and/or amino acid sequence(s) in this application, wherein each "Sequence Listing" is assigned a separate identifier as required in 37 CFR 1.821(c) and 37 CFR 1.822 and 1.823.
- ☒ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 CFR 1.821(d).
- ☐ A copy of each sequence listing submitted for this application in computer readable form, in accordance with the requirements of 37 1.821(e) and 1.824.
- ☒ A statement under 37 CFR 1.821(g) that the content of each paper copy of the sequence listing submitted and each computer readable copy are the same.

Atty's Docket 101195-54


- ☒ A statement under 37 CFR 1.821(g) that the submission includes no new matter.
- ☐ A copy of the NOTICE TO COMPLY...SEQUENCE DISCLOSURES.
- ☐ Other (provide description of items submitted)

**STATEMENT THAT SEQUENCE LISTING  
AND COMPUTER READABLE COPY ARE THE SAME  
AND THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

I hereby state that each computer readable form submitted in this application, is the same as the paper copy of the "Sequence Listing" to which it is indicated to relate. All papers accompanying this submission, or for which a request for transfer from applicant's other application, introduce no new matter.

Respectfully Submitted,

Norris, McLaughlin & Marcus  
220 East 42nd Street  
New York, NY 10017  
Telephone (212) 808-0700  
Facsimile (212) 808-0844

  
Theodore Gottlieb, PhD  
Reg. No. 42, 597